Short Interest in Capstone Therapeutics Corp. (NASDAQ:CAPS) Rises By 210.7%

Posted by on Jun 13th, 2026

Capstone Therapeutics Corp. (NASDAQ:CAPS – Get Free Report) saw a significant increase in short interest during the month of May. As of May 29th, there was short interest totaling 321,408 shares, an increase of 210.7% from the May 14th total of 103,447 shares. Based on an average daily volume of 14,882,138 shares, the days-to-cover ratio is currently 0.0 days. Approximately 4.2% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of Capstone Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a report on Wednesday, June 3rd. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

View Our Latest Research Report on CAPS

Capstone Therapeutics Stock Down 2.2%

Shares of NASDAQ:CAPS traded down $0.01 during midday trading on Friday, reaching $0.30. 167,698 shares of the company were exchanged, compared to its average volume of 6,990,980. Capstone Therapeutics has a fifty-two week low of $0.26 and a fifty-two week high of $2.07. The company has a quick ratio of 0.29, a current ratio of 0.95 and a debt-to-equity ratio of 0.79. The stock has a fifty day simple moving average of $0.39 and a two-hundred day simple moving average of $0.59. The firm has a market cap of $3.73 million, a PE ratio of -0.09 and a beta of -1.54.

Capstone Therapeutics (NASDAQ:CAPS – Get Free Report) last posted its quarterly earnings data on Wednesday, May 20th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.02). The firm had revenue of $12.64 million for the quarter, compared to the consensus estimate of $10.80 million. Capstone Therapeutics had a negative return on equity of 114.15% and a negative net margin of 41.26%.

Institutional Trading of Capstone Therapeutics

An institutional investor recently bought a new position in Capstone Therapeutics stock. DRW Securities LLC purchased a new stake in shares of Capstone Therapeutics Corp. (NASDAQ:CAPS – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 125,422 shares of the company’s stock, valued at approximately $91,000. DRW Securities LLC owned approximately 1.51% of Capstone Therapeutics at the end of the most recent reporting period. Institutional investors own 2.55% of the company’s stock.

Capstone Therapeutics Company Profile

(Get Free Report)

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.

Featured Articles

Receive News & Ratings for Capstone Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capstone Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.